84 related articles for article (PubMed ID: 23692381)
41. Myocardial angiogenesis after plasmid or adenoviral VEGF-A(165) gene transfer in rat myocardial infarction model.
Hao X; Månsson-Broberg A; Grinnemo KH; Siddiqui AJ; Dellgren G; Brodin LA; Sylvén C
Cardiovasc Res; 2007 Feb; 73(3):481-7. PubMed ID: 17134685
[TBL] [Abstract][Full Text] [Related]
42. [Anti-metastatic effect of vascular endothelial growth factor receptor 2 extracellular domain gene-modified dendritic cell vaccination in murine model with experimental pulmonary metastasis].
Pan JP; Weng YS; Wu QQ
Zhonghua Zhong Liu Za Zhi; 2006 Sep; 28(9):646-9. PubMed ID: 17274366
[TBL] [Abstract][Full Text] [Related]
43. Safety evaluation of hemagglutinating virus of Japan--artificial viral envelope liposomes in nonhuman primates.
Tsuboniwa N; Morishita R; Hirano T; Fujimoto J; Furukawa S; Kikumori M; Okuyama A; Kaneda Y
Hum Gene Ther; 2001 Mar; 12(5):469-87. PubMed ID: 11268281
[TBL] [Abstract][Full Text] [Related]
44. Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway.
Isayeva T; Ren C; Ponnazhagan S
Gene Ther; 2007 Jan; 14(2):138-46. PubMed ID: 16943851
[TBL] [Abstract][Full Text] [Related]
45. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance.
Wada H; Satoh N; Kitaoka S; Ono K; Morimoto T; Kawamura T; Nakano T; Fujita M; Kita T; Shimatsu A; Hasegawa K
Atherosclerosis; 2010 Feb; 208(2):512-7. PubMed ID: 19695569
[TBL] [Abstract][Full Text] [Related]
46. Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia.
Wierzbowska A; Robak T; Wrzesień-Kuś A; Krawczyńska A; Lech-Marańda E; Urbańska-Ryś H
Eur Cytokine Netw; 2003; 14(3):149-53. PubMed ID: 14656688
[TBL] [Abstract][Full Text] [Related]
47. Adenovirus-mediated gene transfer into rat livers: comparative study of retrograde intrabiliary and antegrade intraportal administration.
Kuriyama S; Yoshiji H; Nakai S; Deguchi A; Uchida N; Kimura Y; Inoue H; Kinekawa F; Ogawa M; Nonomura T; Masaki T; Kurokohchi K; Watanabe S
Oncol Rep; 2005 Jan; 13(1):69-74. PubMed ID: 15583804
[TBL] [Abstract][Full Text] [Related]
48. Autocrine vascular endothelial growth factor/vascular endothelial growth factor receptor-2 growth pathway represents a cyclooxygenase-2-independent target for the cyclooxygenase-2 inhibitor NS-398 in colon cancer cells.
Kim SJ; Seo JH; Lee YJ; Yoon JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Oncology; 2005; 68(2-3):204-11. PubMed ID: 16015035
[TBL] [Abstract][Full Text] [Related]
49. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
50. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
51. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
52. Safety of direct cardiac administration of AdVEGF-All6A+, a replication-deficient adenovirus vector cDNA/genomic hybrid expressing all three major isoforms of human vascular endothelial growth factor, to the ischemic myocardium of rats.
Kaminsky SM; Quach L; Chen S; Pierre-Destine L; Van de Graaf B; Monette S; Rosenberg JB; De BP; Sondhi D; Hackett NR; Mezey JG; Rosengart TK; Crystal RG
Hum Gene Ther Clin Dev; 2013 Mar; 24(1):38-46. PubMed ID: 23692382
[TBL] [Abstract][Full Text] [Related]
53. [The relativity of vascular endothelium growth factor receptor-1 and preeclampsia].
Zou CL; Liu XH; Yue BM; Fu JH; He GL
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Sep; 37(5):765-8. PubMed ID: 17037747
[TBL] [Abstract][Full Text] [Related]
54. Toxicology and carcinogenesis studies of a binary mixture of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (Cas No. 57465-28-8) and 2,2',4,4',5,5'-hexachlorobiphenyl (PCB 153) (CAS No. 35065-27-1) in female Harlan Sprague-Dawley rats (gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2006 Aug; (530):1-258. PubMed ID: 17160104
[TBL] [Abstract][Full Text] [Related]
55. Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker.
Kanefendt F; Lindauer A; Mross K; Fuhr U; Jaehde U
J Pharm Biomed Anal; 2012 Nov; 70():485-91. PubMed ID: 22819208
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and Safety of Clinical-Grade Human Vascular Endothelial Growth Factor-D
Leikas AJ; Laham-Karam N; Agtereek E; Peltonen HM; Selander T; Korpisalo P; Holappa L; Hartikainen JEK; Heikura T; Ylä-Herttuala S
Hum Gene Ther; 2021 Jul; 32(13-14):761-770. PubMed ID: 33371775
[TBL] [Abstract][Full Text] [Related]
57. [Promising new drugs in the treatment of ovarian cancer, and of gynecologic tumors, in general].
Di Leo A
Tumori; 1999; 85(3 Suppl 1):S27-9. PubMed ID: 10542883
[No Abstract] [Full Text] [Related]
58. Not reinventing the wheel: applying the 3Rs concepts to viral vector gene therapy biodistribution studies.
MacLachlan TK; McIntyre M; Mitrophanous K; Miskin J; Jolly DJ; Cavagnaro JA
Hum Gene Ther Clin Dev; 2013 Mar; 24(1):1-4. PubMed ID: 23692377
[No Abstract] [Full Text] [Related]
59. Development and application of a real-time PCR method for pharmacokinetic and biodistribution studies of recombinant adenovirus.
Xu XX; Shui X; Chen ZH; Shan CQ; Hou YN; Cheng YG
Mol Biotechnol; 2009 Oct; 43(2):130-7. PubMed ID: 19418271
[TBL] [Abstract][Full Text] [Related]
60. Safety and biodistribution of XC001 (encoberminogene rezmadenovec) gene therapy in rats: a potential therapy for cardiovascular diseases.
Stewart DJ; Gianchetti A; Byrnes D; Dittrich HC; Thorne B; Manza LL; Reinhardt RR
Gene Ther; 2024 Jan; 31(1-2):45-55. PubMed ID: 37592080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
